LECTURE series

Do we need high prices to get innovation for small populations?

In this lecture Adrian Towse delves into the intricate world of Orphan Medical Products (OMPs) — therapies meticulously designed for rare diseases that impact small populations.

The central theme of the lecture revolves around the delicate balance between innovation, affordability, and patient well-being within this context.

Adrian explores three critical questions

Is Market Exclusivity (ME) needed to incentivise the Research and Development (R&D) of Orphan Medical Products (OMPs)?

Are R&D costs for individual OMPs lower than those for medicines for more common conditions?

What is a fair price for OMPs?

Write your awesome label here.

Course Le
ssons

Meet the instructor

Adrian Towse

Adrian joined the OHE in 1993 and served as Director for 25 years. Alongside his commitment to OHE, he is a Senior Visiting Fellow at the Health Economics Research Centre, Nuffield Department of Population Health, at the University of Oxford, Adrian also has been a Visiting Professor at the London School of Economics and a Visiting Professor at the University of York. For ten years, he served as a Non-Executive Director of the Oxford University Hospitals NHS Trust, one of the UK’s largest hospital groups. Adrian was President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) for the 2014-15 term and currently serves on its Finance, Governance, and Awards Committees. He currently serves as Vice-Chair of the HTA Committee of the Centre for Innovation in Regulatory Science.
Don't hesitate

Start your learning journey today!